TOP TEN perturbations for 1185_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1185_at
Selected probe(set): 206148_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1185_at (206148_at) across 6537 perturbations tested by GENEVESTIGATOR:

IL-4; GM-CSF study 1 (early) / untreated monocyte sample

Relative Expression (log2-ratio):3.7213707
Number of Samples:6 / 12
Experimental IL-4; GM-CSF study 1 (early)
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 6 hours.
Control untreated monocyte sample
Freshly isolated human monocytes from healthy donors.

Langerhans cell histiocytosis study 1 / normal plasmocytoid dendritic cell sample

Relative Expression (log2-ratio):-3.5181475
Number of Samples:7 / 3
Experimental Langerhans cell histiocytosis study 1
Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity.
Control normal plasmocytoid dendritic cell sample
Normal plasmocytoid dendritic cells were isolated from peripheral blood of healthy adult donors. Plasmocytoid dendritic cells were defined as HLA-DR+ / CD45RAhi / CD11c- / BDCA2+ population.

IL-4; GM-CSF study 1 (intermediate) / untreated monocyte sample

Relative Expression (log2-ratio):3.2734222
Number of Samples:7 / 12
Experimental IL-4; GM-CSF study 1 (intermediate)
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 24 hours.
Control untreated monocyte sample
Freshly isolated human monocytes from healthy donors.

precursor-B-ALL study 3 (hyperdiploid) / T-ALL study 3

Relative Expression (log2-ratio):3.13272
Number of Samples:17 / 29
Experimental precursor-B-ALL study 3 (hyperdiploid)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control T-ALL study 3
Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

ZSTK474 inhibitor (10uM); GM-CSF (1ng/ml) study 1 / mock treated neutrophils (6h)

Relative Expression (log2-ratio):2.8528805
Number of Samples:10 / 10
Experimental ZSTK474 inhibitor (10uM); GM-CSF (1ng/ml) study 1
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with pan phosphoinositide 3-kinase (PI3K) inhibitor ZSTK474 (10uM) and granulocyte macrophage-colony stimulating factor (rhGM-CSF; 1ng/ml) for 6h. ATC code:---
Control mock treated neutrophils (6h)
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with DMSO for 6h.

PI3Kg inhibitor; GM-CSF (1ng/ml) study 1 / mock treated neutrophils (6h)

Relative Expression (log2-ratio):2.787405
Number of Samples:10 / 10
Experimental PI3Kg inhibitor; GM-CSF (1ng/ml) study 1
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with gamma phosphoinositide 3-kinase (PI3Kg) inhibitor and granulocyte macrophage-colony stimulating factor (rhGM-CSF; 1ng/ml) for 6h. ATC code:---
Control mock treated neutrophils (6h)
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with DMSO for 6h.

ZSTK474 inhibitor (10uM); GM-CSF (1ng/ml) study 1 / ZSTK474 study 1 (10uM)

Relative Expression (log2-ratio):2.7860947
Number of Samples:10 / 10
Experimental ZSTK474 inhibitor (10uM); GM-CSF (1ng/ml) study 1
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with pan phosphoinositide 3-kinase (PI3K) inhibitor ZSTK474 (10uM) and granulocyte macrophage-colony stimulating factor (rhGM-CSF; 1ng/ml) for 6h. ATC code:---
Control ZSTK474 study 1 (10uM)
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with 10uM pan phosphoinositide 3-kinase (PI3K) inhibitor ZSTK434 for 6h. ATC code:---

precursor-B-ALL study 3 (PAX5-rearranged) / precursor-B-ALL study 3 (hyperdiploid)

Relative Expression (log2-ratio):-2.521741
Number of Samples:6 / 17
Experimental precursor-B-ALL study 3 (PAX5-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [dic(9;20)(p11-13;q11) )/PAX5 rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control precursor-B-ALL study 3 (hyperdiploid)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

monocyte activation study 1 (NOD2L/TLR/1L; 24h) / untreated monocyte sample (24h)

Relative Expression (log2-ratio):2.4972239
Number of Samples:5 / 5
Experimental monocyte activation study 1 (NOD2L/TLR/1L; 24h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and activated for 24 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L) and 1 ug/ml mycobacterial 19-kDa triacylated lipopeptide (TLR2/1 ligand, TLR2/1L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and heterodimeric Toll-like receptor 2 and Toll-like receptor 1 (TLR2/1).
Control untreated monocyte sample (24h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and collected after 24 hours for RNA isolation.

B-ALL study 1 (hyperdiploid) / normal bone marrow sample

Relative Expression (log2-ratio):2.4833813
Number of Samples:40 / 74
Experimental B-ALL study 1 (hyperdiploid)
Bone marrow samples of patients with hyperdiploid B-ALL (hyperdiploid karyotype).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.